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Neutralization of  LPS 
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John P. Kane,~ and Samuel D. Wright* 
From the *Laboratory of Cellular Physiology and Immunology, The Rockefeller University, 
New York 10021; the *Cardiovascular Research Institute, University of California, 
San Francisco, California 94143; and gAMGEN, Thousand Oaks, California 91320 
Slllnmary 
Lipoproteins i olated from normal human plasma can bind and neutralize bacterial lipopolysaccharide 
(LPS) and may represent an important mechanism in host defense against gram-negative s ptic 
shock. Recent studies have shown that experimentally elevating the levels of circulating high- 
density lipoproteins (HDL) provides protection against death in animal models of endotoxic 
shock. We sought o define the components of HDL that are required for neutralization of LPS. 
To accomplish this we have studied the functional neutralization ofLPS by native and reconstituted 
HDL using a rapid assay that measures the CD14-dependent activation of leukocyte integrins 
on human neutrophils. We report here that reconstituted HDL particles (R-HDL), prepared 
from purified apolipoprotein A-I (apoA-I) combined with phospholipid and free cholesterol, are 
not sufficient o neutralize the biologic activity of LPS. However, addition of recombinant LPS 
binding protein (LBP), a protein known to transfer LPS to CD14 and enhance responses of cells 
to LPS, enabled prompt binding and neutralization of LPS by R-HDL. Thus, LBP appears capable 
of transferring LPS not only to CD14 but also to lipoprotein particles. In contrast with R-HDL, 
apoA-I containing lipoproteins (LpA-I) isolated from plasma by selected affinity immunosorption 
(SAIS) on an anti-apoA-I column, neutralized LPS without addition of exogenous LBP. Several 
lines of evidence demonstrated that LBP is a constituent of LpA-I in plasma. Passage of plasma 
over an anti-apoA-I column removed more than 99% of the LBP detectable by ELISA, whereas 
31% of the LBP was recovered by elution of the column. Similarly, the ability of plasma to 
enable activation of neutrophils by LPS (LBP/Septin activity) was depleted and recovered by 
the same process. Furthermore, an immobilized anti-LBP monoclonal antibody coprecipitated 
apoA-I. The results described here suggest that in addition to its ability to transfer LPS to CD14, 
LBP may also transfer LPS to lipoproteins. Since LBP appears to be physically associated with 
lipoproteins in plasma, it is positioned to play an important role in the neutralization of LPS. 
S tudies over the past few years have shown that plasma pro- teins play an important role in mediating responses of 
cells to low concentrations of bacterial lipopolysaccharide (LPS, 
endotoxin). LPS-binding protein (LBP) 1 (1) and Septin (2) 
interact with LPS and facilitate the binding of the LPS to 
CD14 (3). CD14, a protein found on the surface of mono- 
1 Abbreviations u ed in this paper: AHPBS, APBS with heparin; APBS, PBS 
with 0.5% human serum albumin; apoA-l, apolipoprotein A-I; ELPS, LPS- 
coated sheep erythrocytes; HAP, Dulbecco's PBS with 0.5 U/ml aprotinin, 
0.05% human serum albumin, 3mM D-glucose; LBP, LPS-binding protein; 
LNF, LPS-neutralizing factor; Lp(A-I), apoA-I containing lipoproteins; 
NHP, normal human plasma; PC, phosphatidylcholine; PDEDTA, 
Dulbecco's PBS lacking Ca 2+ and Mg 2+ with 1 mM EDTA; R-HDL, 
reconstituted high-density lipoproteins; rLBP, recombinant human LBP; 
SAIS, selected affinity immunosorption. 
cytes, macrophages, and neutrophils (4) then initiates responses 
of these cells (5, 6). CD14 is also found as a soluble protein 
in the plasma, and complexes of LPS with soluble CD14 par- 
ticipate in responses of endothelial cells (7), epithelial cells 
(8), and probably other cell types that do not express mem- 
brane CD14. These studies have emphasized the ability of 
plasma to potentiate responses to LPS. 
In contrast, anumber of older studies have focused on the 
ability of plasma to inactivate ndotoxin (9-11). Incubation 
of LPS with plasma has been shown to block the ability of 
the LPS to cause fever and death in experimental nimals (10, 
11) and to block the ability of LPS to give a positive signal 
in the Limulus amebocyte lysate assay (12, 13). This "detoxifica- 
tion" or neutralization of LPS is thought o occur without 
covalent modification of the LPS, because the LPS detoxified 
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by plasma can be extracted with organic solvents and shows 
full activity (14). Here we reconcile the findings of both poten- 
tiating and neutralizing activity in plasma. By using a very 
rapid assay of cell stimulation, we show that plasma first poten- 
tiates responses to LPS, with maximal activity observed in 
about 10 min. Thereafter, plasma neutralizes the LPS. These 
studies suggest hat the relative kinetics of potentiation and 
neutralization may dictate the responses of mammalian cells 
to endotoxin. 
Work from several laboratories has shown that plasma li- 
poproteins, particularly high-density lipoproteins (HDL), bind 
and neutralize LPS (15-18), and that these particles may con- 
stitute the LPS-neutralizing activity in plasma. Here we show 
that HDL-like particles reconstituted from purified compo- 
nents cannot by themselves neutralize LPS, but the LPS neu- 
tralizing capacity of these particles can be realized by the ad- 
dition of purified LBP. These studies suggest hat LBP is an 
LPS transfer protein that facilitates binding of LPS not only 
to CD14 but also to lipoproteins. We further found that LBP 
in plasma is associated with lipoproteins, suggesting an im- 
portant role for LBP in the neutralization of LPS by plasma. 
Materials and Methods 
Reagents. LPS from Salmonella minnesota strain K595 (Re) and 
3H-labeled LPS from Escherichia coli K12 strain LCD25 (K12) was 
purchased from List Biological Laboratories (Campbell, CA). 
Human serum albumin was purchased from Armour Pharmaceu- 
tical Co. (Kankakee, IL). Recombinant human (r)LBP was expressed 
and purified as described (3). Polyclonal anti-rLBP was raised in 
rabbits and purified by chromatography on protein G-Sepharose. 
17G4 is a routine mAb (IgG2a) directed against LBP (Myc, A., 
and D. Emanuel, manuscript in preparation). It was purified from 
ascites fluid by chromatography on protein G-Sepharose. Purified 
egg phosphatidylcholine, cholesterol, and sodium cholate were pur- 
chased from Sigma Chemical Co. (St. Louis, MO). Normal human 
plasma (NHP) was prepared from the blood of healthy donors an- 
ticoagulated with 5 U/ml sodium heparin and stored at 4~ 
Depletion of Apolipoprotein A-I from NHP. NHP was depleted 
of apolipoprotein A-I (apoA-I) using selected affinity immunosorp- 
tion (SAIS) as previously described (19, 20). NHP passed through 
a column of Sepharose coupled to a goat anti-human apoA-I IgG 
was shown to be >95% depleted of apoA-I by ELISA (Kunitake, 
S. T., andJ. P. Kane, manuscript inpreparation). Recovery of apoA-I 
from the column by elution with 0.2 M acetic acid, 150 mM NaC1 
(pH 3.0) was >90%. The resulting preparation of apoA-I containing 
lipoproteins (Lp(A-I)) has been characterized previously (19). As 
a control, NHP was passed over a preimmune IgG column and 
showed no detectable oss of apoA-I from the flow through and 
no recovery of apoA-I in the acid eluate. The goat anti-human apoA-I 
antibody used to prepare the immunoaffinity column was shown 
not to recognize LBP by ELISA (see Fig. 10) or Western blot (data 
not shown). 
Preparation ofReconstituted HDL (R-HDL) Particles. K-HDL were 
prepared by the sodium cholate dialysis method as previously de- 
scribed (21). Briefly, apoA-I, purified by sequential u tracentrifuga- 
tion and size exclusion chromatography as previously described (22) 
was mixed with egg phosphatidylcholine (PC), cholesterol, and 
cholate at a ratio of 80:4:1:80 (PC/cholesterol/apoA-I/cholate) nd
cholate was removed with extensive dialysis against PDEDTA (Dub 
becco's PBS lacking Ca z+ and Mg ~+ with 1 mM EDTA) con- 
taining 0.01% sodium azide. Another mixture was prepared in par- 
allel in which PC and cholesterol were omitted (apoA-I alone). 
Incorporation of apoA-I protein into lipid-containing particles of 
'~200 kD was confirmed by gel filtration using a Superose 6 column 
(60 x 1.8 cm; Pharmacia LKB, Piscataway, NJ) and by non- 
denaturing polyacrylamide g l electrophoresis using an 8-25% gel 
run on the Pharmacia Phast System (Pharmacia LKB). Final prepa- 
rations were stored in PDEDTA with 0.01% azide at 4~ Im- 
mediately before use in assays of the bioactivity of LPS, the apoA-I 
preparations were exchanged into APBS (PBS with 0.5% human 
serum albumin) by ultrafiltration i a Centricon 10 (Amicon Corp., 
Beverly, MA). 
ELISA for Quantitation of LBP. A 72-well Terasaki plate 
(Robbins Scientific Corp., Sunnyvale, CA) was coated with anti- 
LBP mAb 17G4 (5/~g/ml) then blocked with PD containing 10% 
nonfat milk. The plate was then washed with PD containing Tween 
20 (0.05%) and samples, diluted in PD containing 0.1% nonfat 
milk, were added to the plate for 1 h at room temperature. The 
plate was then washed and rabbit anti-human rLBP (5/~g/ml in 
PD with 0.1% nonfat milk) was added for 1 h at room tempera- 
ture. The plate was washed again and alkaline phosphatase- 
conjugated goat anti-rabbit IgG (Bio-Rad Laboratories Inc., Rich- 
mond, CA) (1:1,500 in PD with 0.1% nonfat milk) was added to 
the wells. After a further 35-min incubation at room temperature, 
the plate was washed and bound alkaline phosphatase was mea- 
sured using the fluorogenic suhstrate Attophos (JBL Scientific, San 
Luis Obispo, CA) and a Cytofluor 2300 (Millipore Corp., Bed- 
ford, MA) fluorescence plate reader. Each plate included astandard 
curve of known concentrations of rLBP diluted in PD with 0.1% 
milk. 
To observe the interaction of LBP with apoA-I, Terasaki wells 
were coated with 5/~g/ml of mAb 17G4, a mAb directed against 
human apoA-I, type II (Calbiochem-Novabiochem, San Diego, CA), 
or control mAb 26ic directed against CD14 (23) for 2 h at 21~ 
Plates were blocked with 0.5% gelatin as described (24), and dilu- 
tions of rLBP, purified apoA-I, or partially purified lipoproteins 
were added for 30 min at 21~ Plates were then washed and in- 
cubated with either goat anti-apoA-I (10/~g/ml) or with a rabbit 
anti-LBP (10/~g/ml). Bound secondary antibody was detected with 
alkaline phosphatase-conjugated nti-goat (Bio-Rad Laboratories 
Inc.) or anti-rabbit IgG as described above. 
Partially purified lipoproteins were obtained by passing NHP 
over a column loaded with HiPak TM aldehyde (ChromatoChem, Inc., 
Missoula, MT). This procedure quantitatively removed LBP/Septin 
activity from NHP. The column was eluted with 0.5 M ammo- 
nium acetate, pH 3.0, and the eluate was immediately applied to 
a G-25 Sephadex column to change the buffer to PDEDTA. This 
eluate contained 90% of the original LBP/Septin activity of plasma 
but <1% of the protein of plasma (Park, C. T., and S. D. Wright, 
manuscript in preparation). 
Stimulation of PMN by LPS. To assess the biologic activity of 
LPS we measured adhesion of human PMN to fibrinogen-coated 
surfaces as described (25). In this assay, stimulation of PMN adhe- 
sion depends on the binding of LPS to cell surface CD14 and re- 
quires LBP or Septin (LBP/Septin activity) to facilitate this binding. 
Adhesion of the stimulated PMN to fibrinogen is mediated by the 
leukocyte integrin CD11b/CD18 (CR3, Mac1). Briefly, mixtures 
containing LPS and a source of LBP or Septin were diluted in APBS 
or AHPBS (APBS with 4 U/ml sodium heparin) to the concentra- 
tions indicated, yielding a final volume of 50/~1. 10/~1 of freshly 
isolated PMN (2 x 107 cells/ml in HAP [Dulbecco's PBS with 
0.5 U/ml aprotinin, 0.05% human serum albumin, 3 mM D-glu- 
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cose]) ftuorescently labeled with 5-(and 6-) carboxyfluorescein d - 
acetate, succinimidyl ester as described (3, 25) were added and in- 
cubated for 10 rain at 37~ to stimulate the cells. PMN were then 
washed into HAP and added to a 72-weU Terasaki plate precoated 
with fibrinogen. After 15 min at 37~ adherence of PMN to the 
plate was quantitated. The fluorescence in each well was measured 
using a Cytofluor 2300 as a way of quantitating the total number 
of cells/well. The plate was then washed and the plate was read 
again. Binding is expressed as the percentage of cells remaining 
in the well after the washing step (percent adhesion). Since stimu- 
lation of the PMN requires both LPS and LBP/Septin (Fig. 1), assays 
performed in the presence of excess LBP measure the available con- 
centration of LPS. In a similar fashion, assays performed in the pres- 
ence of excess LPS measure the available concentration of 
LBP/Septin. Donor to donor variation in maximal responses 
(20-75% adhesion) prohibited averaging results of separate experi- 
ments, but the pattern of responses was very reproducible. 
Neutralization fLPS. LPS was incubated with lipoprotein or 
NHP diluted in AHPBS for 0-2 h at 37~ The amount of avail- 
able LPS remaining in the tube was assessed by adjusting the LBP 
concentration to 0.5-1.0/~g/ml, adding PMN, and measuring adhe- 
sion as described above. 
Binding of LPS-coated Erythrocytes to Macrophages. The binding 
of LPS-coated sheep erythrocytes (ELPS) opsonized with plasma, 
by CD14 on cultured human macrophages was performed as de- 
scribed (26). Briefly, ELPS were prepared by incubating 10/~g of 
sonicated LPS (R595) with 10 s sheep erythrocytes for I h at 37~ 
ELPS were washed extensively and resuspended to a concentration 
of 10 s cells/ml in EDTA-GVB 2- (5 mM veronal buffer, pH 7.5, 
with 150 mM NaC1, 0.1% gelatin, 1 mM EDTA). To determine 
the ability of NHP to promote the binding of ELPS to macro- 
phages, equal volumes of ELPS and a 1:50 dilution of NHP in 
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Figure 1. NHP first potentiates then neutralizes the capacity of LPS 
to stimulate PMN. E. coli K12 LPS (1 ng/ml) was incubated for the stated 
intervals at 37~ with NHP (10%) (Q, O). At the end of this period, 
buffer (Q) or rLBP (1 #g/ml) (O) and fluorescently labeled PMN were 
added. After 10 rain at 37~ the binding of PMN to fibrinogen was mea- 
sured as described in Materials and Methods. Fresh LPS (1 ng/ml) added 
after the 120-rain i cubation with plasma (  9  restored cellular adhesion. 
rLBP (1/~g/ml) was su~cient to enable aresponse when mixed with LPS 
(1 ng/ml) just before addition of PMN (11). "Control" represents PMN 
treated with LPS alone (W) or NHP alone ( 9  Each point represents 
the mean of 3 wells 4- SD of a representative experiment repeated three 
times. 
PDEDTA were incubated for the stated time at 37~ The resulting 
opsonized ELPS were washed, resuspended in EDTA-GVB z-, and 
5 x 10 s red cells were added to a monolayer of macrophages in 
a Terasaki well. After a 15-min incubation at room temperature, 
unbound ELPS were removed by inverting the plate for 10 min 
at room temperature and gently washing the monolayer. Binding 
of ELPS was evaluated by phase contrast microscopy and expressed 
as the attachment index, the number of erythrocytes bound per 
100 macrophages. 
Binding of 3H-labeled LPS to R-HDL. To measure binding of 
LPS to R.-HDL, 3H-LPS (100 ng/ml, specific activity ~ 1,000 
dpm/10ng), IL-HDL (100/xg/ml), and rLBP (0-10/~g/ml) were 
diluted in I ml of APBS and incubated at 37~ for I h. The solu- 
tion was then cooled to 0~ brought o a density of 1.12 g/ml 
with a saturated potassium bromide solution, placed in a 5-ml Quick- 
Seal TM tube (Beckman Instruments, Palo Alto, CA) and spun in 
a Vti 65.2 rotor (Beckman Instruments) ata temperature of 10~ 
for 9 h at 60,000 rpm. The contents of each tube were separated 
into equal top and bottom fractions and the amount of radioac- 
tivity in I ml of each fraction was evaluated by scintillation counting 
in 3 ml of Ready Safe TM (Beckman Instruments). Preliminary studies 
demonstrated that under similar conditions, >90% of [3H]phos- 
phatidylcholine-labeled R-HDL was found in the top half of the 
tube. apoA-I protein detected by Western blot, also migrated to 
the top of the tube under these conditions. 
Results 
The Ability of LPS to Stimulate PMN Is Rapidly Enhanced 
and then Slowly Neutralized upon Incubation in NHP. LPS 
(1 ng/ml) was incubated with NHP (10%) at 37~ for the 
intervals shown in Fig. 1. The ability of the resulting mix- 
ture to stimulate cells was quantitated by adding PMN for 
10 min and measuring the attachment of the cells to immobi- 
lized fibrinogen. LPS alone did not stimulate adhesion of PMN 
to fibrinogen, but upon incubation of LPS with NHP, the 
ability of LPS to stimulate adhesion was very rapidly enabled 
(Fig. 1). Stimulation was evident even when LPS and NHP 
were combined immediately before the 10-min incubation 
with PMN (0-rain incubation) and was maximal with a 10- 
min incubation. We attribute this rapid enabling effect to 
LBP and/or Septin in the plasma nd henceforth we will refer 
to this activity, seen at the early time of incubation, as 
LBP/Septin activity. Longer periods of incubation with NHP 
resulted in a gradual oss of the ability of LPS to stimulate 
PMN. After 120 min, >80% of the stimulatory capacity of 
the mixture was lost. The loss in activity over time was due 
to the loss of available LPS rather than the loss or degrada- 
tion of LBP/Septin because addition of LPS at the end of 
the incubation restored responses while addition of rLBP did 
not (Fig. 1). Thus, the loss of the ability of LPS to stimulate 
cells after incubation in NHP results from neutralization of 
the LPS, and the factor(s) responsible for this neutralization 
we will refer to as LPS-neutralizing factor or LNF. Because 
incubation of LPS in NHP for times longer than 120 min 
resulted in only minor additional oss of activity we chose 
120 min as the standard time of incubation to demonstrate 
LNF activity. 
The ability of plasma to transiently enable recognition of 
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LPS by cells was confirmed in studies that measure the binding 
of ELPS to CD14 on macrophages. ELPS were incubated with 
2% NHP for intervals, washed, and binding to macrophages 
was assessed (Fig. 2). Incubation of ELPS with plasma (5 
min) enabled strong binding to macrophages, but further in- 
cubation caused complete loss of this binding capacity. This 
loss of binding was not due to the instability of LBP/Septin 
deposited on the ELPS surface because ELPS incubated with 
NHP for 5 min, washed to remove unbound protein, and 
incubated another 35 rain at 37~ retained the ability to bind 
macrophages. Furthermore, the fall in binding observed after 
long incubation with NHP was not caused by loss of LBP/- 
Septin activity because NHP recovered after the incubation 
with the ELPS retained the ability to promote binding of 
fresh ELPS to macrophages, and addition of fresh NHP or 
LBP to the treated ELPS did not restore binding to macro- 
phages (data not shown). Finally, it is unlikely that the fall 
in binding was caused by loss of LPS from the erythrocyte 
since ELPS formed with 3H-labeled LPS demonstrated only 
a slow loss of <9% of the LPS between the 5- and 40-min 
time points (data not shown). These results confirm that 
plasma contains activities that first enable recognition of LPS 
by cells and then cause neutralization of the LPS. 
R-HDL Does Not Bind or Neutralize LPS. Several labora- 
tories have demonstrated that LPS added to blood or plasma 
binds to lipoproteins uch as HDL resulting in a complex 
with reduced biological activity (15-18). Therefore we ex- 
amined the role of HDL particles in the neutralization of
LPS. All HDL particles contain apoA-I, but these particles 
also contain substoichiometric amounts of at least 17 other 
proteins (24, 27-31). To obtain a homogeneous preparation, 
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Figure 2. NHP enables then inhibits the binding of ELPS to macro- 
phages. ELPS were incubated for the stated period with NHP (2%) (I), 
washed into EDTAGVB 2-, added to a monolayer ofmacrophages, and 
binding of erythrocytes was evaluated as described in Materials and Methods. 
Data are expressed as attachment i dex, the number of erythrocytes bound 
per 100 macrophages, and are the mean values • SD for three wells of 
a representative experiment repeated three times. ELPS incubated with 
NHP 5 min, washed, and incubated another 35 rain at 37~ showed no 
decrease in binding to macrophages (O). In this experiment, ELPS in the 
absence of LBP or NHP gave an attachment i dex of 5. 
we reconstituted HDL particles from purified apoA-I, phos- 
phatidylcholine, and cholesterol. 
Binding of LPS to lipoprotein was measured by incubating 
3H-LPS with R-HDL for 1 h at 37~ followed by ultracen- 
trifugation at a density of 1.12 g/ml to separate R-HDL (den- 
sity <1.12 g/ml) from the relatively higher density 3H-LPS 
(Fig. 3). Addition of R-HDL caused no increase in the amount 
of 3H-LPS found at density <1.12 g/ml, indicating that no 
binding to R-HDL had occurred. In similar studies, LPS 
(1 ng/ml) was incubated with an amount of R-HDL approx- 
imating that found in 10% NHP (100 #g/ml), for times up 
to 2 h, but no neutralization of biological activity was ob- 
served (Fig. 4). Thus, R-HDL by itself cannot bind or neu- 
tralize LPS. 
rLBP Enables R-HDL to Rapidly Bind and Neutralize LPS. 
We have previously shown that LBP acts as an LPS transfer 
protein, catalyzing the binding of LPS to CD14 (3). We rea- 
soned, therefore, that LBP may be able to transfer LPS into 
R-HDL and cause neutralization f the LPS. Indeed, we ob- 
served that LBP enabled a dose-dependent i crease in the 
amount of 3H-LPS fractionating with R-HDL (Fig. 3). As- 
sociation of 3H-LPS with R-HDL appeared maximal at an 
LBP concentration of 1 /~g/ml. Under these conditions, 
'~30% of the 3H-LPS was shifted to the upper, HDL-con- 
taining fraction by the addition of LBP. 
Parallel studies howed that LBP also enabled R-HDL to 
neutralize the biologic activity of LPS (Fig. 4). Neutraliza- 
tion of LPS by R-HDL and LBP was rapid and complete, 
with >50% neutralization occurring in 40 min and >88% 
by 120 min. We confirmed the requirement for LBP in the 
neutralization of LPS by R-HDL using several concentra- 
tions of LPS (Fig. 5). Addition of 1 #g/ml rLBP enabled 
R-HDL to strongly neutralize >30 ng/ml LPS, but R-HDL 
in the absence of LBP caused no neutralization fLPS at any 
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Figure 3. Binding of LPS to R-HDL depends on the concentration 
of rLBP. 3H-LPS (100 ng/ml) was incubated with increasing concentra- 
tions ofrLBP in the presence (0) or absence (O) of R-HDL (100/zg/ml) 
for 1 h at 37~ After ultracentrifugation at density = 1.12 g/ml, the 
top and bottom half of each tube were separated and the amount of 3H- 
LPS assessed byscintillation counting. The data is presented as the cpm 
measured in the top half of each tube (density <1.12 g/ml) as a percentage 
of the total recovered in each tube. Results are representative of two iden- 
tical studies and three similar studies using a fixed dose of LBP. 
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Figure 4. Time dependence of the neutralization f LPS by R-HDL 
and rLBP. E. coli K12 LPS (1 ng/ml) was incubated with R.-HDL (100 
/~g/ml apoA-I) for the stated times in the presence (O) or absence (O) 
of rLBP (0.5/~g/ml). The amount of biologically active LPS remaining 
was assessed by adjusting the LBP concentration f all samples to 0.5/~g/ml 
and adhesion of PMN to fibrinogen was measured. No stimulation of adhe- 
sion was seen with buffer alone (~7), LPS alone (A), or LPS with rHDL 
( I ) .  Each point represents he mean of 3 wells _+ SD of a representative 
experiment repeated three times. 
dose. When the dose of LPS was adjusted to 100 ng/ml, LBP 
caused neutralization of "~30% of the biologic activity (Fig. 
5). This fraction corresponds well to the 30% of 3H-LPS 
transferred to R-HDL under similar conditions (Fig. 3). 
Substoichiometric amounts of rLBP were sufficient to en- 
able neutralization of LPS by R-HDL. Half-maximal neu- 
tralization of 10 ng/ml of LPS by R-HDL was seen with 
0.01 #g/ml of rLBP (Fig. 6). Under these conditions, each 
molecule of LBP (Mr ~- 60,000) (1) neutralized at least 
seven molecules of LPS (Mr ~ 4,000) (32) in the presence 
of R-HDL. This result further confirms that LBP enables 
neutralization fLPS by R-HDL and suggests hat LBP func- 
tions catalytically inthis role. In contrast to R-HDL, apoA-I 
alone did not neutralize LPS, and the addition of even high 
concentrations of LBP did not enable neutralization. This 
result shows that neither LBP nor apoA-I has any LPS neu- 
tralizing activity and suggests an obligate role for lipids in 
LPS neutralization by rHDL. 
Lp(A-I) Particles Represent Only Part of the LNF Activity in 
Plasma. To assess the contribution of Lp(A-I) particles to 
LNF activity in plasma, we used SAIS to remove Lp(A-I) 
particles from whole plasma nd to recover purified Lp(A-I) 
particles. Chromatography on anti-apoA-I removed >95% 
of the apoA-I from plasma, but removed only small amounts 
of the LNF activity (Fig. 7). The amount of LNF activity 
removed varied from preparation to preparation, but removal 
of apoA-I from NHP never resulted inmore than a 66% reduc- 
tion in the amount of LPS neutralized. This observation sug- 
gests that Lp(A-I) particles are not the only lipoprotein par- 
ticles involved in neutralization of LPS. This finding is 
consistent with studies demonstrating a role for very low 
density lipoprotein (VLDL) in the neutralization fLPS (33). 
We also tested the purified Lp(A-I) particles for LNF ac- 
tivity. Lp(A-I) particles demonstrated very strong LNF ac- 
tivity, almost completely neutralizing 10 ng/ml of R595 LPS 
(Fig. 7). No LNF activity was eluted from the control preim- 
mune column (data not shown). The ef~cient neutralization 
of LPS by Lp(A-I) particles demonstrates that like R-HDL, 
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Figure 5. LBP enables neutralization f high concentrations of LPS 
by R-HDL. Increasing concentrations ofE. coli K12 LPS were incubated 
with buffer ( i )  or R-HDL (100 #g/ml apoA-I) (A, A) in the presence 
( I ,  A) or absence (A) of rLBP (1/~g/ml) for 2 h at 37~ The amount 
of biologicaUy active LPS remaining was assessed by adjusting the final 
rLBP concentration in all samples to 1/zg/ml, adding PMN and measur- 
ing binding to fibrinogen. Each point represents the mean of three wells +- 
SD of a representative experiment repeated three times. 
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Figure 6. NeutralizationofLPSbyR-HDLdependsontheconcentra- 
tion of rLBP. Increasing concentrations of rLBP were incubated with K12 
LPS (10 ng/ml) for 2 h at 37~ with apoA-I ( I ) ,  or R-HDL (A), both 
at a concentration f 100/~g/ml apoA-l. The biologically active LPS re- 
maining was assessed by raising the rLBP concentration by 1/~g/ml in 
all tubes, adding PMN and measuring adhesion to fibrinogen. No stimu- 
lation of adhesion was seen with LPS alone (Y). Each point represents 
the mean of three wells -+ SD of a representative experiment repeated 
three times. 
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Figure 7. Lp(A-I) particles exhibit LNF activity. Increasing concen- 
trations of R595 LPS were incubated for 2 h at 37~ with buffer (AHPBS) 
alone ( I ,  A), 10% NHP (O), 10% apoA-I depleted plasma (O), or 10% 
purified Lp(A-I) particles (V) (dilutions normalized to the starting volume 
of NHP). At the end of this incubation, buffer ( I )  or rLBP (A, 0 ,  O, 
IV) was added to 0.5 #g/ml, PMN were added and adhesion to fibrinogen 
coated surfaces was evaluated. LPS alone caused no stimulation of PMN 
( I ) .  LNF activity is represented here by the difference between LBP- 
stimulated adhesion (A) and the loss of that stimulatory capacity (arrow). 
Each point represents the mean of three wells of an experiment selected 
from a set of three. 
native HDL particles are also able to neutralize LPS. How- 
ever, the neutralization of LPS by purified Lp(A-I) particles 
showed no dependence on exogenously added LBP. This 
finding suggested that native Lp(A-I) particles possess alipid 
transfer protein with the same function as LBP. We there- 
fore asked whether LBP itself was present in these particles. 
LBV/Septin Activity Copurifies with Lp(A-I) Panicles. Lp(A-I) 
particles were assayed for LBP/Septin by measuring their ability 
to enable responses of PMN to LPS after a lO-min incuba- 
tion. We observed strong LBP/Septin activity in Lp(A-I) par- 
ticles as shown by the large increase in PMN adhesion over 
LPS alone (Fig. 8 A). In contrast, plasma depleted of apoA-I 
showed a marked reduction in LBP/Septin activity such that 
~1,000 times more LPS was required to observe the level 
of adhesion seen in the presence of Lp(A-I). The copurification 
of LBP/Septin activity with Lp(A-I) was confirmed by meas- 
uring the ability of fractions to enable binding of ELPS to 
macrophages (Fig. 8 B). NHP demonstrated strong LBP/ 
Septin activity in this assay, enabling avid binding of ELPS 
to macrophages. In contrast, plasma depleted of Lp(A-I) by 
passage over the anti-apoA-I column was devoid of this ac- 
tivity, promoting no binding of ELPS. Greater than 62% 
of the LBP/Septin activity observed in this assay, was recov- 
ered in the eluate from the anti-apoA-I column (purified Lp(A-I) 
particles). A nonspecific loss of activity from NHP of '~35 % 
was seen after passage over a preimmune IgG column, but 
no activity was recovered in the eluate from this column, 
confirming that LBP/Septin activity specifically copurifies with 
Lp(A-I) particles. These results indicate that Lp(A-I) parti- 
des bear not only LNF activity but also bear LBP/Septin 
activity, and that nearly all the LBP/Septin activity in plasma 
resides on Lp(A-I) particles. 
We confirmed the association of both LNF and LBP/Septin 
activity with apoA-I containing particles by following the 
kinetics of PMN stimulation by LPS and purified Lp(A-I) 
particles. LPS was incubated for various times with either 
purified Lp(A-I) particles or with the eluate from a control, 
preimmune column (Fig. 9). The capacity of LPS to stimu- 
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Figure 8. LBWSeptin activity copurifies with Lp(A-I) particles. (A) The 
indicated concentrations of R595 LPS were incubated for 10 rain at 37~ 
in the presence of buffer (AHPBS) alone (m), 10% NHP (O), 10% apoA- 
I depleted plasma (O), 10% purified Lp(A-I) particles (IF), or 10% preim- 
mune control (sham) depleted plasma (  9  The ability of these mixtures 
to stimulate adhesion of PMN to fibrinogen was measured. Each point 
represents the mean of three wells of a representative experiment repeated 
three times. (B) ELPS were incubated in the presence of a 1:80 dilution 
of the indicated samples for 10 rain at 37~ Treated ELPS were washed, 
added to a monolayer of macrophages, and binding was evaluated as de- 
scribed in Materials and Methods. Each bar represents the mean of three 
wells --- SD of a representative experiment repeated three times. 
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Figure 9. Lp(A-I) particles contain both LBP/Septin and LNF activi- 
ties. R595 LPS (10 ng/ml) was incubated for the stated times at 37~ 
in the presence of10% eluate from a preimmune IgG column (A, A) 
or 10% purified Lp(A-I) particles (O, 0). At the end of this incubation, 
buffer (AHPBS) (A, O) or rLBP (0.5/xg/ml) (A, O) was added, and 
the mixture was incubated an additional 10 min, PMN were then added 
and binding of PMN to fibrinogen-coated w lls was measured. LPS alone 
(R) did not stimulate c lls. Each point represents the mean of three wells 
+- SD of a representative experiment repeated three times. 
late PMN was rapidly enabled by Lp(A-I) particles, thus 
demonstrating LBP/Septin activity. Upon further incubation, 
the mixture lost the ability to stimulate PMN. This loss of 
activity was due to neutralization f the LPS since addition 
of rLBP at the end of the incubation was not able to restore 
activity. The eluate from the control preimmune column 
showed no LBP/Septin or LNF activity, demonstrating that 
these activities are specifically associated with Lp(A-I) parti- 
cles. These studies also show that the sequential enabling and 
neutralization f LPS-mediated responses observed in whole 
plasma (Fig. 1) may be recapitulated with purified Lp(A-I) 
particles. 
LBP Is Physically Associated with Lp(A-I) Particles. Because 
the above functional data suggested that LBP may be present 
in the Lp(A-I) particles, we measured LBP associated with 
these particles by ELISA (Table 1). NHP was found to con- 
tain 2.8/~g/ml of LBP. Depletion of Lp(A-I) particles re- 
duced LBP to undetectable levels (>99% depletion). Lp(A-I) 
particles eluted from the column contained 0.88 #g/ml of 
LBP whereas LBP was undetectable in the eluate from the 
control preimmune column. Thus, LBP detected by ELISA 
is specifically retained by the anti-apoA-I column suggesting 
that LBP is physically associated with Lp(A-I) particles. 
We performed the reciprocal experiment (capture of apoA-I 
with anti-LBP) using a modified ELISA (Fig. 10). Solutions 
of lipoprotein particles were incubated in plates coated with 
anti-LBP mAb 17G4. This step results in capture of both 
LBP and any associated apolipoproteins. ApoA-I associated 
with the captured LBP was then detected using polyclonal 
anti-apoA-I. Since NHP contains a high concentration of
apoA-I ('~1 mg/ml), nonspecific binding of this protein from 
plasma precluded etection of a signal above background. We 
therefore performed the analysis using partially purified lipo- 
protein particles isolated by chromatography on a column 
of HiPak TM Aldehyde. This procedure results in quantitative 
recovery of LBP/septin activity from plasma but a 100-fold 
reduction in protein concentration (Park, C. T., and S. D. 
Wright, manuscript in preparation). Anti-LBP mAb 17G4 
captured not only LBP but also apoA-I from this solution 
(Fig. 10 A). This observation confirms physical association 
of LBP with apoA-I containing lipoproteins. Under iden- 
tical conditions, urface-bound monoclonal nti-apoA-I cap- 
tured a small amount of LBP (Fig. 10 B). We believe this 
is due to the fact that the immobilized anti-apoA-I mAb is 
saturated and capture of the apoA-I is thus incomplete. Ex- 
periments with lower concentrations of partially purified li- 
poproteins showed capture of up to 79% of the LBP with 
anti-apoA-I (data not shown). 
Parallel studies confirmed the efficacy and specificity of the 
antibodies used above. Surface-bound anti-LBP mAb 17G4 
Table 1. LBP Content (Izg/ml) in Immunoaflinity Column Fractions 
Expt. no. NHP 
Flow through Eluate Flow through Eluate 
anti-apoA-I anti-apoA-I preimmune preimmune 
column column column column 
1 3.75 <0.025 1.00 1.50 <0.025 
2 1.50 <0.025 1.03 1.13 <0.025 
3 3.25 <0.025 0.63 2.50 <0.025 
Average 2.80 <0.025 0.88 1.71 <0.025 
NHP from three separate individuals was subjected toimmunoaffinity adsorption  a column coupled with goat anti-human poA-I gG or goat 
preimmune IgG. Fractions were qualized tothe starting volume of plasma, nd the concentration of LBP levels was determined by ELISA as described 
in Materials and Methods. Values given are the LBP concentration n/.tg/ml. Each value is the mean of triplicate wells. The limit of detection of
the ELISA is 0.025 /~g/ml LBP. 
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Figure 10. Anti-LBP captures apoA-I. Terasaki plates were coated with 
mAbs against LBP (hatched bars), apoA-I (solid bars), or CD14 (open bars) 
followed by addition of rLBP (0.1/~g/ml), apoA-I (0.1 #g/ml), or par- 
tially purified lipoproteins (5/~g/ml) for 30 min. Captured apoA-I was 
detected with rabbit anti-apoA-I (A) and captured LBP was detected with 
rabbit anti-rLBP (B). Background signal (no LBP or lipoprotein added) 
was determined for each combination f immobilized antibody and sec- 
ondary antibody and was subtracted from the data shown. Each bar 
represents the mean _+ SD of a representative experiment repeated three 
times. 
captured purified rLBP as detected with a rabbit anti-LBP 
antibody (Fig. 10). No rLBP was captured if the 17G4 was 
replaced with an irrelevant monoclonal, confirming the 
specificity of this mAb, and the rabbit anti-LBP did not de- 
tect apoA-I captured by another monoclonal antibody, 
confirming the specificity of this polyclonal antibody. In a 
similar fashion, surface-bound anti-apoA-I captured purified 
apoA-I as detected with the goat anti-apoA-I second antibody. 
No apoA-I was captured if the monoclonal anti-apoA-I was 
replaced with an irrelevant monoclonal. It is important o 
note that the polyclonal anti-apoA-I did not detect LBP cap- 
tured by 17G4 indicating that it does not recognize LBP (Fig. 
10 A). Since this polyclonal anti-apoA-I antibody was used 
in the affinity isolation of Lp(A-I) particles described above, 
the coisolation of LBP with apoA-I observed above is un- 
likely to be an artifact caused by crossreactivity of the goat 
anti-apoA-I with LBP. 
Discussion 
We have developed an assay for the biologic activity of LPS 
that requires only a 10-min exposure of LPS-containing samples 
to cells, and we have used this assay to measure the kinetics 
of LPS neutralization i NHP. This assay contrasts with other 
assays used in the study of in vitro neutralization ofLPS (e.g., 
production of cytokines by monocytes) which require at least 
4 h incubation of cells with samples and are therefore blind 
to the rapid changes in the availability of LPS described here. 
Using our assay we found that plasma first enabled LPS to 
stimulate cells, with activity reaching apeak within 10 min. 
Subsequently, the ability of LPS to stimulate cells slowly de- 
creased over the next 2 h. This decline was not due to a loss 
of LBP/Septin activity in the plasma but to sequestration f
the LPS in a form which was no longer available for LBP- 
mediated transfer to cell surface CD14. Thus, plasma con- 
tains factors which sequentially enable then neutralize the 
biological effects of LPS. 
Despite the well-documented ability of HDL to bind and 
neutralize LPS in plasma (15-18), and studies howing that 
intravenous R-HDL protects against death in animal models 
of endotoxic shock (34, 35) we showed that R-HDL parti- 
cles alone, reconstituted from highly purified components 
(apoA-I, PC, and cholesterol), were unable to bind or neu- 
tralize purified LPS. The inability of LPS to spontaneously 
interact with R-HDL is consistent with the biophysical prop- 
erties of LPS and phospholipids. These membrane-forming 
amphiphiles diffuse very slowly between bilayers, and ap- 
preciable movement of phospholipids i  only observed in the 
presence of proteins uch as phospholipid exchange proteins 
(36) which catalyze interbilayer movement. We observed, how- 
ever, that addition of rLBP to R-HDL enabled rapid, po- 
tent, dose-dependent binding and neutralization of LPS by 
R-HDL. By analogy with other lipid exchange proteins, we 
believe that LBP enables neutralization of LPS by facilitating 
its diffusion from LPS vesicles or micelles into HDL. This 
hypothesis  consistent with previous tudies that have shown 
that binding of LPS by lipoproteins i a necessary step in the 
neutralization of LPS (16, 18). 
rLBP enabled effective neutralization of LPS at doses ub- 
stoichiometric tothe dose of LPS neutralized. Each molecule 
of LBP caused neutralization of at least seven molecules of 
LPS under the conditions hown in Fig. 6. This result im- 
plies that LBP acts catalytically to transfer LPS to R-HDL. 
Thus, LBP appears to catalytically transfer LPS to at least 
two destinations, CD14 as we have recently described (3) and 
now HDL. 
We find that LBP circulates in plasma ssociated with apoA-I. 
Over 99% of LBP detected by ELISA and virtually all of 
the LBP/Septin activity was removed from plasma by pas- 
sage over an anti-apoA-I column, and both LBP/Septin ac- 
tivity and LBP protein was recovered in the eluate from the 
anti-apoA-I column. Reciprocal studies howed that an im- 
mobilized mAb against LBP captured not only LBP but also 
apoA-I (Fig. 10). LBP thus joins a group of over 17 apolipo- 
proteins that associate with apoA-I-containing lipoproteins 
(24, 27-31). Because of the relative abundance of LBP (~5 
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#g/ml) (37) and apoA-I ("~1 mg/ml) in plasma, it is likely 
that fewer than one in 100 HDL particles bear an LBP. ApoA- 
I-containing lipoproteins are tremendously heterogeneous in 
composition, and our studies do not identify other constitu- 
ents in Lp(A-I) particles associated with LBP. 
Our studies how that neutralization ofLPS requires both 
lipoprotein and an enzyme to catalyze movement of LPS into 
the lipoprotein. ApoA-I-containing lipoproteins bear both 
of these components and consequently are strong neutralizers 
of LPS (Fig. 7). Removal of apoA-I from plasma, however, 
caused only partial oss of LPS neutralizing activity (Fig. 7). 
Since apoA-I-depleted plasma contains abundant lipoproteins 
(LDL, VLDL), only a transfer enzyme is needed for neutral- 
ization to be observed. Fig. 6 shows that as little as 0.01/zg/ml 
of LBP can catalyze significant neutralization of LPS in the 
presence of excess lipoprotein. It is possible, therefore, that 
the small amount of LBP remaining in the apoA-I-depleted 
plasma is sufficient o enable neutralization fLPS. We cannot 
rule out the possibility, however, that an additional transfer 
activity exists in plasma. 
Our finding that lipoproteins in plasma carry all the neces- 
sary cofactors for neutralization fLPS appears to differ from 
previous work. Studies with ultracentrifugally isolated lipo- 
proteins demonstrated that neutralization of LPS required 
factors found in the nonlipoprotein fraction (16, 17). We be- 
lieve this difference r sults from the methods used to prepare 
lipoproteins. The SAIS procedure used here is a far gentler 
procedure than ultracentrifugation and is known to preserve 
the association of proteins with HDL. For example, the as- 
sociation of transferrin (31) with HDL is disturbed by ultracen- 
trifugal isolation but preserved by SAIS. Therefore, we be- 
lieve that lipoproteins isolated by SAIS do not require 
exogenous cofactors uch as LBP to neutralize LPS because 
LBP remains bound to Lp(A-I) particles. 
LBP shows strong sequence homology with cholesterol 
ester transfer protein (CETP) (1) and phospholipid transfer 
protein (PLTP) (38) (23 and 24% identity, respectively). CETP 
is associated with HDL and transfers cholesterol esters and 
triglycerides between lipoproteins (39). PLTP is also associated 
with HDL and transfers phospholipids into HDL (40). LBP 
thus appears to be part of an emerging family of proteins 
characterized bysequence homology, association with HDL, 
and the capacity to transfer lipid species between lipopro- 
teins. An additional homologous protein, bactericidal per- 
meability increasing factor (BPI) (1), resides not on lipopro- 
teins but on the membranes ofthe primary granules of PMN 
(41). Lipid transfer activity has not yet been demonstrated 
for BPI. 
The dual role of LBP in both enabling and inhibiting re- 
sponses to LPS makes it difficult o predict whether its effects 
are predominantly to enhance or to blunt responses to LPS. 
A dominant role for LBP in the neutralization ofLPS might 
be inferred from the observation that LBP is an acute phase 
reactant, rising from <5/zg/ml to >60/~g/ml after challenge 
(37), and plasma from patients in the acute phase exhibits 
a reduced ability to enable cytokine production by mono- 
cytes in response to LPS (42). Alternatively, LBP may also 
have an important role in enabling responses to LPS, and factors 
such as the affinity of LBP for lipoproteins may modulate 
which activity predominates. 
ApoA-I-containing lipoproteins have all the necessary com- 
ponents for both enabling and neutralizing the bioactivity 
of LPS. In fact, these purified particles recapitulated the se- 
quential enabling and neutralizing of LPS-mediated responses 
(Fig. 9) observed with whole plasma (Fig. 1). Thus, HDL 
sits at a crossroads in LPS trafficking. Transfer of LPS to CD14 
results in a biologically active complex, while retention by 
lipoproteins neutralizes LPS. It is possible that yet other factors 
in plasma influence the direction of trafficking of LPS and 
thereby modulate biological responses to LPS after it enters 
the bloodstream. We are currently searching for such factors. 
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